Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.42 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.42 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671559 | 0.91 | ADORA2A (0.48) | ADORA2AADORA2BSLC29A1 | |
| Bromide SCHEMBL9672114 | 0.90 | ADORA2A (0.47) | ADORA2AADORA2BSLC29A1 | |
| SCHEMBL5601329 | 0.90 | ADORA2A (0.52) | ADORA2AADORA2BADORA1SLC28A2 | |
| SCHEMBL9670813 | 0.90 | ADORA2A (0.49) | ADORA2AADORA2BSLC29A1ADORA1 | |
| SCHEMBL965396 | 0.89 | ADORA2A (0.52) | ADORA2AADORA2BSLC29A1ADORA1 | |
| SCHEMBL9671634 | 0.87 | ADORA2A (0.47) | ADORA2AADORA2BSLC29A1ADORA1 | |
| SCHEMBL9671694 | 0.87 | ADORA2A (0.41) | ADORA2AADORA2BADORA1 | |
| SCHEMBL9672030 | 0.87 | SLC29A1 (0.47) | ADORA2AADORA2BSLC29A1ADORA1SLC28A2 | |
| SCHEMBL9671626 | 0.86 | ADORA2A (0.46) | ADORA2AADORA2BSLC29A1ADORA1 | |
| SCHEMBL9670797 | 0.86 | ADORA2A (0.42) | ADORA2AADORA2BSLC29A1ADORA1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5102873-A | Viricides | SOUTHERN RESEARCH INSTITUTE (US) | 1992-04-07 | — | — | US | claimed |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
| EP-1868628-B1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS | CHIMERIX INC (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8642577-B2 | Compounds, compositions and methods for the treatment of poxvirus infections | CHIMERIX, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013165898-A2 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20100316991-A1 | HUMAN PARAINFLUENZA VIRUS TYPE 3 EXPRESSING THE ENHANCED GREEN FLUORESCENT PROTEIN FOR USE IN HIGH-THROUGHPUT ANTIVIRAL ASSAYS | UTAH STATE UNIVERSITY (US) | 2010-12-16 | — | — | US | disclosed |
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | 2007-01-04 | — | — | US | disclosed |
| US-5102873-A | Viricides | SOUTHERN RESEARCH INSTITUTE (US) | 1992-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003516-A1 | Compounds, compositions and methods for the treatment of poxvirus infections | IFNG, POLI, STING1 | ADORA2A 2217/4885ADORA2B 3315/4885SLC29A1 1753/4885 |
| US-20150094327-A1 | COMPOSITIONS AND METHODS FOR INHIBITING RESOLVASES | FEN1, RCE1, APEX1 | ADORA2A 1691/4885ADORA2B 2690/4885SLC29A1 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.